Epigenetic alterations involved in cancer stem cell reprogramming

Molecular Oncology

Volumn 6, Issue 6, 2012, Pages 620-636

  Muñoz, Purificación ^a   Iliou, Maria S ^a   Esteller, Manel ^a,b,c  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Cancer stem cells; DNA methylation; Epigenetics; Histone modifications; MicroRNAs

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; MICRORNA; NOTCH RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER STEM CELL; CELL PROLIFERATION; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HEDGEHOG; HISTONE MODIFICATION; HUMAN; METASTASIS; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

EID: 84869880156     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.10.006     Document Type: Review

References (248)

1. Abdouh M., Facchino S., Chatoo W., Balasingam V., Ferreira J., Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J. Neurosci. 2009, 29:8884-8896.
2. Ahn Y.H., Gibbons D.L., Chakravarti D., Creighton C.J., Rizvi Z.H., Adams H.P., Pertsemlidis A., Gregory P.A., Wright J.A., Goodall G.J., et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J. Clin. Invest. 2012, 122:3170-3183.
3. Akiyama Y., Maesawa C., Ogasawara S., Terashima M., Masuda T. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am. J. Pathol. 2003, 163:1911-1919.
4. Alcantara Llaguno S., Chen J., Kwon C.H., Jackson E.L., Li Y., Burns D.K., Alvarez-Buylla A., Parada L.F. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
5. Ali S., Ahmad A., Banerjee S., Padhye S., Dominiak K., Schaffert J.M., Wang Z., Philip P.A., Sarkar F.H. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 2010, 70:3606-3617.
6. Arumugam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Logsdon C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
7. Ateeq B., Unterberger A., Szyf M., Rabbani S.A. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008, 10:266-278.
8. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S., et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
9. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell. Biol. 2012, 198:281-293.
10. Bandres E., Agirre X., Bitarte N., Ramirez N., Zarate R., Roman-Gomez J., Prosper F., Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 2009, 125:2737-2743.
11. Bao B., Ali S., Banerjee S., Wang Z., Logna F., Azmi A.S., Kong D., Ahmad A., Li Y., Padhye S., Sarkar F.H. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 2012, 72:335-345.
12. Bar E.E., Lin A., Mahairaki V., Matsui W., Eberhart C.G. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am. J. Pathol. 2010, 177:1491-1502.
13. Barker N., Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 2006, 5:997-1014.
14. Bernstein B.E., Humphrey E.L., Erlich R.L., Schneider R., Bouman P., Liu J.S., et al. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(13):8695-8700.
15. Berx G., Cleton-Jansen A.M., Strumane K., de Leeuw W.J., Nollet F., van Roy F., Cornelisse C. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13:1919-1925.
16. Biegel J.A., Fogelgren B., Zhou J.Y., James C.D., Janss A.J., Allen J.C., Zagzag D., Raffel C., Rorke L.B. Mutations of the INI1 rhabdoid tumor suppressor gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous system. Clin. Cancer Res. 2000, 6:2759-2763.
17. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16(1):6-21.
18. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
19. Bloushtain-Qimron N., Yao J., Snyder E.L., Shipitsin M., Campbell L.L., Mani S.A., Hu M., Chen H., Ustyansky V., Antosiewicz J.E., et al. Cell type-specific DNA methylation patterns in the human breast. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14076-14081.
20. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
21. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D'Urso L., Pagliuca A., Biffoni M., Labbaye C., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14:1271-1277.
22. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
23. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 2010, 29:613-639.
24. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006, 20:1123-1136.
25. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., Goodall G.J. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008, 68:7846-7854.
26. Burdach S., Plehm S., Unland R., Dirksen U., Borkhardt A., Staege M.S., Muller-Tidow C., Richter G.H. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. Cell Cycle 2009, 8:1991-1996.
27. Burk U., Schubert J., Wellner U., Schmalhofer O., Vincan E., Spaderna S., Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9:582-589.
28. Cairo S., Wang Y., de Reynies A., Duroure K., Dahan J., Redon M.J., Fabre M., McClelland M., Wang X.W., Croce C.M., Buendia M.A. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20471-20476.
29. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
30. Canettieri G., Di Marcotullio L., Greco A., Coni S., Antonucci L., Infante P., Pietrosanti L., De Smaele E., Ferretti E., Miele E., et al. Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat. Cell. Biol. 2010, 12:132-142.
31. Cano A., Perez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F., Nieto M.A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell. Biol. 2000, 2:76-83.
32. Cao Q., Yu J., Dhanasekaran S.M., Kim J.H., Mani R.S., Tomlins S.A., Mehra R., Laxman B., Cao X., Yu J., et al. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27:7274-7284.
33. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
34. Comijn J., Berx G., Vermassen P., Verschueren K., van Grunsven L., Bruyneel E., Mareel M., Huylebroeck D., van Roy F. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell. 2001, 7:1267-1278.
35. Cottonham C.L., Kaneko S., Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J. Biol. Chem. 2010, 285:35293-35302.
36. Cozzio A., Passegue E., Ayton P.M., Karsunky H., Cleary M.L., Weissman I.L. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003, 17:3029-3035.
37. Crea F., Fornaro L., Bocci G., Sun L., Farrar W.L., Falcone A., Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012, 31(3-4):753-761.
38. Crea F., Hurt E.M., Mathews L.A., Cabarcas S.M., Sun L., Marquez V.E., Danesi R., Farrar W.L. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol. Cancer 2012, 10:40.
39. Cui H., Cruz-Correa M., Giardiello F.M., Hutcheon D.F., Kafonek D.R., Brandenburg S., Wu Y., He X., Powe N.R., Feinberg A.P. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003, 299:1753-1755.
40. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., Yu W.H., Rehman S.K., Hsu J.L., Lee H.H., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell. Biol. 2011, 13:317-323.
41. Chang C.J., Yang J.Y., Xia W., Chen C.T., Xie X., Chao C.H., Woodward W.A., Hsu J.M., Hortobagyi G.N., Hung M.C. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100.
42. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell. 2007, 26:745-752.
43. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
44. Chiou S.H., Wang M.L., Chou Y.T., Chen C.J., Hong C.F., Hsieh W.J., Chang H.T., Chen Y.S., Lin T.W., Hsu H.S., Wu C.W. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010, 70:10433-10444.
45. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., Samuel S., Kim M.P., Lim S.J., Ellis L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69:1951-1957.
46. De Smet C., De Backer O., Faraoni I., Lurquin C., Brasseur F., Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:7149-7153.
47. Dews M., Fox J.L., Hultine S., Sundaram P., Wang W., Liu Y.Y., Furth E., Enders G.H., El-Deiry W., Schelter J.M., et al. The myc-miR-17∼92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res. 2010, 70:8233-8246.
48. Dohadwala M., Yang S.C., Luo J., Sharma S., Batra R.K., Huang M., Lin Y., Goodglick L., Krysan K., Fishbein M.C., et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006, 66:5338-5345.
49. Driessens G., Beck B., Caauwe A., Simons B.D., Blanpain C. Defining the mode of tumour growth by clonal analysis. Nature 2012, 488:527-530.
50. Du J., Yang S., An D., Hu F., Yuan W., Zhai C., Zhu T. BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell. Res. 2009, 19:487-496.
51. Dumont N., Wilson M.B., Crawford Y.G., Reynolds P.A., Sigaroudinia M., Tlsty T.D. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:14867-14872.
52. Dunbier A., Guilford P. Hereditary diffuse gastric cancer. Adv. Cancer Res. 2001, 83:55-65.
53. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., Pickell K., Aguilar J., Lazetic S., Smith-Berdan S., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:e2428.
54. Eberle I., Pless B., Braun M., Dingermann T., Marschalek R. Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells. Nucleic Acids Res. 2010, 38:5384-5395.
55. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300:455.
56. Eger A., Aigner K., Sonderegger S., Dampier B., Oehler S., Schreiber M., Berx G., Cano A., Beug H., Foisner R. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24:2375-2385.
57. Eramo A., Ricci-Vitiani L., Zeuner A., Pallini R., Lotti F., Sette G., Pilozzi E., Larocca L.M., Peschle C., De Maria R. Chemotherapy resistance of glioblastoma stem cells. Cell. Death Differ. 2006, 13:1238-1241.
58. Ernst A., Campos B., Meier J., Devens F., Liesenberg F., Wolter M., Reifenberger G., Herold-Mende C., Lichter P., Radlwimmer B. De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene 2010, 29:3411-3422.
59. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
60. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
61. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
62. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
63. Ferretti E., De Smaele E., Miele E., Laneve P., Po A., Pelloni M., Paganelli A., Di Marcotullio L., Caffarelli E., Screpanti I., et al. Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. Embo J. 2008, 27:2616-2627.
64. Fodde R., Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell. Biol. 2007, 19:150-158.
65. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
66. Fukuda S., Taga T. Cell fate determination regulated by a transcriptional signal network in the developing mouse brain. Anat. Sci. Int. 2005, 80:12-18.
67. Gangaraju V.K., Lin H. MicroRNAs: key regulators of stem cell. Nat. Rev. Mol. Cell. Biol. 2009, 10(2):116-125.
68. Garzia L., Andolfo I., Cusanelli E., Marino N., Petrosino G., De Martino D., Esposito V., Galeone A., Navas L., Esposito S., et al. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 2009, 4:e4998.
69. Ghoshal P., Nganga A.J., Moran-Giuati J., Szafranek A., Johnson T.R., Bigelow A.J., Houde C.M., Avet-Loiseau H., Smiraglia D.J., Ersing N., et al. Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res. 2009, 69:4380-4387.
70. Gibbons D.L., Lin W., Creighton C.J., Rizvi Z.H., Gregory P.A., Goodall G.J., Thilaganathan N., Du L., Zhang Y., Pertsemlidis A., Kurie J.M. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009, 23:2140-2151.
71. Giovannetti E., Funel N., Peters G.J., Del Chiaro M., Erozenci L.A., Vasile E., Leon L.G., Pollina L.E., Groen A., Falcone A., et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010, 70:4528-4538.
72. Gopisetty, G., Xu, J., Sampath, D., Colman, H., Puduvalli, V.K. Epigenetic regulation of CD133/PROM1 expression in glioma stem cells by Sp1/myc and promoter methylation. Oncogene, http://dx.doi.org/10.1038/onc.2012.331.
73. Grand F., Kulkarni S., Chase A., Goldman J.M., Gordon M., Cross N.C. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia. Cancer Res. 1999, 59:3870-3874.
74. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol. 2008, 10:593-601.
75. Guarino M., Rubino B., Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39:305-318.
76. Guo Y., Pakneshan P., Gladu J., Slack A., Szyf M., Rabbani S.A. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J. Biol. Chem. 2002, 277:41571-41579.
77. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nat. Med. 2009, 15:1010-1012.
78. Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59:177-189.
79. Han M., Liu M., Wang Y., Chen X., Xu J., Sun Y., Zhao L., Qu H., Fan Y., Wu C. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One 2012, 7:e39520.
80. Hanahan D., Coussens L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
81. Hashimoto Y., Akiyama Y., Otsubo T., Shimada S., Yuasa Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis 2010, 31:777-784.
82. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
83. Heddleston J.M., Li Z., McLendon R.E., Hjelmeland A.B., Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
84. Heddleston J.M., Wu Q., Rivera M., Minhas S., Lathia J.D., Sloan A.E., Iliopoulos O., Hjelmeland A.B., Rich J.N. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell. Death Differ. 2012, 19:428-439.
85. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
86. Herranz N., Pasini D., Diaz V.M., Franci C., Gutierrez A., Dave N., Escriva M., Hernandez-Munoz I., Di Croce L., Helin K., et al. Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 2008, 28:4772-4781.
87. Herrera-Merchan A., Arranz L., Ligos J.M., de Molina A., Dominguez O., Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat. Commun. 2012, 3:623.
88. Hiltunen M.O., Alhonen L., Koistinaho J., Myohanen S., Paakkonen M., Marin S., Kosma V.M., Janne J. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int. J. Cancer 1997, 70:644-648.
89. Hirata H., Hinoda Y., Ueno K., Nakajima K., Ishii N., Dahiya R. MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer. Carcinogenesis 2012, 33:501-508.
90. Ho L., Crabtree G.R. Chromatin remodelling during development. Nature 2010, 463(7280):474-484.
91. Holm T.M., Jackson-Grusby L., Brambrink T., Yamada Y., Rideout W.M., Jaenisch R. Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 2005, 8:275-285.
92. Huang S., He X., Ding J., Liang L., Zhao Y., Zhang Z., Yao X., Pan Z., Zhang P., Li J., et al. Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int. J. Cancer 2008, 123:972-978.
93. Hughes D.P. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat. Res. 2009, 152:479-496.
94. Hussain M., Rao M., Humphries A.E., Hong J.A., Liu F., Yang M., Caragacianu D., Schrump D.S. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 2009, 69:3570-3578.
95. Hwang-Verslues W.W., Chang P.H., Wei P.C., Yang C.Y., Huang C.K., Kuo W.H., Shew J.Y., Chang K.J., Lee E.Y., Lee W.H. miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 2011, 30(21):2463-2474.
96. Hwang J.H., Voortman J., Giovannetti E., Steinberg S.M., Leon L.G., Kim Y.T., Funel N., Park J.K., Kim M.A., Kang G.H., et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010, 5:e10630.
97. Iliopoulos D., Lindahl-Allen M., Polytarchou C., Hirsch H.A., Tsichlis P.N., Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell. 2010, 39:761-772.
98. Ingham P.W., Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nat. Rev. Genet. 2006, 7:841-850.
99. Inui M., Martello G., Piccolo S. MicroRNA control of signal transduction. Nat. Rev. Mol. Cell. Biol. 2010, 11:252-263.
100. Jagani Z., Mora-Blanco E.L., Sansam C.G., McKenna E.S., Wilson B., Chen D., Klekota J., Tamayo P., Nguyen P.T., Tolstorukov M., et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat. Med. 2010, 16:1429-1433.
101. Ji J., Yamashita T., Budhu A., Forgues M., Jia H.L., Li C., Deng C., Wauthier E., Reid L.M., Ye Q.H., et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009, 50:472-480.
102. Ji Q., Hao X., Meng Y., Zhang M., Desano J., Fan D., Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.
103. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009, 4:e6816.
104. Jiang J., Hui C.C. Hedgehog signaling in development and cancer. Dev. Cell. 2008, 15:801-812.
105. Jiang X., Tan J., Li J., Kivimae S., Yang X., Zhuang L., Lee P.L., Chan M.T., Stanton L.W., Liu E.T., et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008, 13:529-541.
106. Jin X., Jeon H.Y., Joo K.M., Kim J.K., Jin J., Kim S.H., Kang B.G., Beck S., Lee S.J., Kim J.K., et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res. 2011, 71(8):3066-3075.
107. Johnson S.M., Grosshans H., Shingara J., Byrom M., Jarvis R., Cheng A., Labourier E., Reinert K.L., Brown D., Slack F.J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
108. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
109. Jones S., Wang T.L., Shih Ie M., Mao T.L., Nakayama K., Roden R., Glas R., Slamon D., Diaz L.A., Vogelstein B., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
110. Kagara N., Huynh K.T., Kuo C., Okano H., Sim M.S., Elashoff D., Chong K., Giuliano A.E., Hoon D.S. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am. J. Pathol. 2012, 181:257-267.
111. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell. Rev. 2007, 3:30-38.
112. Kefas B., Comeau L., Floyd D.H., Seleverstov O., Godlewski J., Schmittgen T., Jiang J., diPierro C.G., Li Y., Chiocca E.A., et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J. Neurosci. 2009, 29:15161-15168.
113. Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D., Green R., Farnham P.J. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 2004, 18:1592-1605.
114. Klarmann G.J., Decker A., Farrar W.L. Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008, 3:59-63.
115. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 2006, 31(2):89-97.
116. Koizume S., Tachibana K., Sekiya T., Hirohashi S., Shiraishi M. Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells. Nucleic Acids Res. 2002, 30:4770-4780.
117. Kong D., Banerjee S., Ahmad A., Li Y., Wang Z., Sethi S., Sarkar F.H. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010, 5:e12445.
118. Kong D., Heath E., Chen W., Cher M.L., Powell I., Heilbrun L., Li Y., Ali S., Sethi S., Hassan O., et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012, 7:e33729.
119. Kong W., Yang H., He L., Zhao J.J., Coppola D., Dalton W.S., Cheng J.Q. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28:6773-6784.
120. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
121. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
122. Krivtsov A.V., Twomey D., Feng Z., Stubbs M.C., Wang Y., Faber J., Levine J.E., Wang J., Hahn W.C., Gilliland D.G., et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006, 442:818-822.
123. Kuang W., Tan J., Duan Y., Duan J., Wang W., Jin F., Jin Z., Yuan X., Liu Y. Cyclic stretch induced miR-146a upregulation delays C2C12 myogenic differentiation through inhibition of Numb. Biochem. Biophys. Res. Commun. 2009, 378:259-263.
124. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
125. Lapouge G., Youssef K.K., Vokaer B., Achouri Y., Michaux C., Sotiropoulou P.A., Blanpain C. Identifying the cellular origin of squamous skin tumors. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(18):7431-7436.
126. Lee K.K., Workman J.L. Hisotne acetyltransferase complex: one size doesn't fit all. Nat. Rev. Mol. Cell. Biol. 2007, 8(4):284-295.
127. Lee J., Son M.J., Woolard K., Donin N.M., Li A., Cheng C.H., Kotliarova S., Kotliarov Y., Walling J., Ahn S., et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13:69-80.
128. Lee T.I., Jenner R.G., Boyer L.A., Guenther M.G., Levine S.S., Kumar R.M., Chevalier B., Johnstone S.E., Cole M.F., Isono K., et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006, 125:301-313.
129. Li X., Gonzalez M.E., Toy K., Filzen T., Merajver S.D., Kleer C.G. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am. J. Pathol. 2009, 175:1246-1254.
130. Li X., Pan Y.Z., Seigel G.M., Hu Z.H., Huang M., Yu A.M. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol. 2011, 81:783-792.
131. Li Y., Guessous F., Zhang Y., Dipierro C., Kefas B., Johnson E., Marcinkiewicz L., Jiang J., Yang Y., Schmittgen T.D., et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009, 69:7569-7576.
132. Li Y., VandenBoom T.G., Kong D., Wang Z., Ali S., Philip P.A., Sarkar F.H. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009, 69:6704-6712.
133. Li Z., Rich J.N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr. Top. Microbiol. Immunol. 2010, 345:21-30.
134. Lindvall C., Bu W., Williams B.O., Li Y. Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell. Rev. 2007, 3:157-168.
135. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med. 2011, 17:211-215.
136. Liu S., Tetzlaff M.T., Cai R., Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Am. J. Pathol. 2012, 181(5):1823-1835.
137. Liu, Z.L., Wang, H., Liu, J., Wang, Z.X. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem., (PMID: 22956424). http://dx.doi.org/10.1016/j.yexcr.2012.07.019.
138. Lo W.L., Yu C.C., Chiou G.Y., Chen Y.W., Huang P.I., Chien C.S., Tseng L.M., Chu P.Y., Lu K.H., Chang K.W., et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J. Pathol. 2011, 223:482-495.
139. Lombaerts M., van Wezel T., Philippo K., Dierssen J.W., Zimmerman R.M., Oosting J., van Eijk R., Eilers P.H., van de Water B., Cornelisse C.J., Cleton-Jansen A.M. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 2006, 94:661-671.
140. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setien F., Casado S., Suarez-Gauthier A., Sanchez-Cespedes M., Git A., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007, 67:1424-1429.
141. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
142. Ma S., Tang K.H., Chan Y.P., Lee T.K., Kwan P.S., Castilho A., Ng I., Man K., Wong N., To K.F., et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010, 7:694-707.
143. Majumdar A., Curley S.A., Wu X., Brown P., Hwang J.P., Shetty K., Yao Z.X., He A.R., Li S., Katz L., et al. Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:530-538.
144. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
145. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
146. May R., Riehl T.E., Hunt C., Sureban S.M., Anant S., Houchen C.W. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 2008, 26:630-637.
147. May R., Sureban S.M., Lightfoot S.A., Hoskins A.B., Brackett D.J., Postier R.G., Ramanujam R., Rao C.V., Wyche J.H., Anant S., Houchen C.W. Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G303-G310.
148. McDonald O.G., Wu H., Timp W., Doi A., Feinberg A.P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 2012, 18:867-874.
149. Merlos-Suarez A., Barriga F.M., Jung P., Iglesias M., Cespedes M.V., Rossell D., Sevillano M., Hernando-Momblona X., da Silva-Diz V., Munoz P., et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2012, 8:511-524.
150. Mestdagh P., Bostrom A.K., Impens F., Fredlund E., Van Peer G., De Antonellis P., von Stedingk K., Ghesquiere B., Schulte S., Dews M., et al. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol. Cell. 2010, 40:762-773.
151. Miele L., Miao H., Nickoloff B.J. NOTCH signaling as a novel cancer therapeutic target. Curr. Cancer Drug Targets 2006, 6:313-323.
152. Misawa A., Katayama R., Koike S., Tomida A., Watanabe T., Fujita N. AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol. Res. 2010, 19:23-33.
153. Mohyeldin A., Garzon-Muvdi T., Quinones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
154. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009, 8:1067-1074.
155. Nagel R., le Sage C., Diosdado B., van der Waal M., Oude Vrielink J.A., Bolijn A., Meijer G.A., Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res. 2008, 68:5795-5802.
156. Nakamura N., Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin. Exp. Metastasis 1998, 16:471-479.
157. Nishigaki M., Aoyagi K., Danjoh I., Fukaya M., Yanagihara K., Sakamoto H., Yoshida T., Sasaki H. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res. 2005, 65:2115-2124.
158. Northcott P.A., Fernandez L.A., Hagan J.P., Ellison D.W., Grajkowska W., Gillespie Y., Grundy R., Van Meter T., Rutka J.T., Croce C.M., et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res. 2009, 69:3249-3255.
159. Ogawa O., Eccles M.R., Szeto J., McNoe L.A., Yun K., Maw M.A., Smith P.J., Reeve A.E. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 1993, 362:749-751.
160. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., Mohammad H.P., Chen W., Daniel V.C., Yu W., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39:237-242.
161. Okano M., Bell D.W., Hber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99(3):247-257.
162. Otte A.P., Kwaks T.H. Gene expression by Polycomb group of protein complexes: a distinct complex for every occasion?. Curr. Opin. Genet. Dev. 2003, 13(5):448-454.
163. Pang R.T., Leung C.O., Ye T.M., Liu W., Chiu P.C., Lam K.K., Lee K.F., Yeung W.S. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010, 31:1037-1044.
164. Park J.K., Lee E.J., Esau C., Schmittgen T.D. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009, 38:e190-199.
165. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
166. Pasca di Magliano M., Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer 2003, 3:903-911.
167. Pece S., Serresi M., Santolini E., Capra M., Hulleman E., Galimberti V., Zurrida S., Maisonneuve P., Viale G., Di Fiore P.P. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell. Biol. 2004, 167:215-221.
168. Peinado H., Ballestar E., Esteller M., Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol. 2004, 24:306-319.
169. Perez-Pomares J.M., Munoz-Chapuli R. Epithelial-mesenchymal transitions: a mesodermal cell strategy for evolutive innovation in Metazoans. Anat. Rec. 2002, 268:343-351.
170. Petrocca F., Vecchione A., Croce C.M. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008, 68:8191-8194.
171. Pierce G.B., Speers W.C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res. 1988, 48:1996-2004.
172. Plikus M.V., Mayer J.A., de la Cruz D., Baker R.E., Maini P.K., Maxson R., Chuong C.M. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration. Nature 2008, 451:340-344.
173. Polakis P. Wnt signaling and cancer. Genes Dev. 2000, 14:1837-1851.
174. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9:265-273.
175. Qian B., Katsaros D., Lu L., Preti M., Durando A., Arisio R., Mu L., Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat. 2009, 117:131-140.
176. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
177. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., Burow M.E., Ivan M., Croce C.M., Nephew K.P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
178. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell. 2007, 26:731-743.
179. Reisman D., Glaros S., Thompson E.A. The SWI/SNF complex and cancer. Oncogene 2009, 28:1653-1668.
180. Reisman D.N., Sciarrotta J., Wang W., Funkhouser W.K., Weissman B.E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 2003, 63:560-566.
181. Rendl M., Polak L., Fuchs E. BMP signaling in dermal papilla cells is required for their hair follicle-inductive properties. Genes Dev. 2008, 22:543-557.
182. Ringrose L., Paro R. Epigenetic regulation of cellular memory by Polycomb and THritorax group proteins. Annu. Rev. Genet. 2004, 38:413-443.
183. Rizzo S., Hersey J.M., Mellor P., Dai W., Santos-Silva A., Liber D., Luk L., Titley I., Carden C.P., Box G., et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol. Cancer Ther. 2011, 10:325-335.
184. Roberts C.W., Orkin S.H. The SWI/SNF complex-chromatin and cancer. Nat. Rev. Cancer 2004, 4:133-142.
185. Santos-Rosa H., Schneider R., Bannister A.J., Sherriff J., Bernstein B.E., Emre N.C., et al. Active genes are tri-methylated at K4 of histone H3. Nature 2002, 419(6905):407-411.
186. Saydam O., Shen Y., Wurdinger T., Senol O., Boke E., James M.F., Tannous B.A., Stemmer-Rachamimov A.O., Yi M., Stephens R.M., et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol. Cell. Biol. 2009, 29:5923-5940.
187. Schepers A.G., Snippert H.J., Stange D.E., van den Born M., van Es J.H., van de Wetering M., Clevers H. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012, 337:730-735.
188. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39:232-236.
189. Schoenhals M., Kassambara A., De Vos J., Hose D., Moreaux J., Klein B. Embryonic stem cell markers expression in cancers. Biochem. Biophys. Res. Commun. 2009, 383:157-162.
190. Seidel S., Garvalov B.K., Wirta V., von Stechow L., Schanzer A., Meletis K., Wolter M., Sommerlad D., Henze A.T., Nister M., et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983-995.
191. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
192. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
193. Shiao S.L., Ganesan A.P., Rugo H.S., Coussens L.M. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011, 25:2559-2572.
194. Shimono Y., Zabala M., Cho R.W., Lobo N., Dalerba P., Qian D., Diehn M., Liu H., Panula S.P., Chiao E., et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138:592-603.
195. Siu, M.K., Wong, E.S., Kong, D.S., Chan, H.Y., Jiang, L., Wong, O.G., Lam, E.W., Chan, K.K., Ngan, H.Y., Le, X.F., Cheung, A. N. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene, http://dx.doi.org/10.1038/onc.2012.363.
196. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
197. Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., Lee S.H., Park W.S., Yoo N.J., Lee J.Y., Nam S.W. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005, 113:264-268.
198. Sparmann A., van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 2006, 6:846-856.
199. Stylianou S., Clarke R.B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66:1517-1525.
200. Sun J.F., Sui J.L., Zhou P.K., Geng Y., Hu Y.C., Cao Z.S., Ge S.L., Lou T.Z., Wu D.C. Decreased efficiency of gamma-ray-induced DNA double-strand break rejoining in malignant transformants of human bronchial epithelial cells generated by alpha-particle exposure. Int. J. Radiat. Biol. 2002, 78:773-780.
201. Sun J.Y., Huang Y., Li J.P., Zhang X., Wang L., Meng Y.L., Yan B., Bian Y.Q., Zhao J., Wang W.Z., et al. MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. Biochem. Biophys. Res. Commun. 2012, 420:787-792.
202. Sureban S.M., May R., Lightfoot S.A., Hoskins A.B., Lerner M., Brackett D.J., Postier R.G., Ramanujam R., Mohammed A., Rao C.V., et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res. 2011, 71:2328-2338.
203. Suva M.L., Riggi N., Janiszewska M., Radovanovic I., Provero P., Stehle J.C., Baumer K., Le Bitoux M.A., Marino D., Cironi L., et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009, 69:9211-9218.
204. Suzuki H., Watkins D.N., Jair K.W., Schuebel K.E., Markowitz S.D., Chen W.D., Pretlow T.P., Yang B., Akiyama Y., Van Engeland M., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat. Genet. 2004, 36:417-422.
205. Swarbrick A., Woods S.L., Shaw A., Balakrishnan A., Phua Y., Nguyen A., Chanthery Y., Lim L., Ashton L.J., Judson R.L., et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat. Med. 2010, 16:1134-1140.
206. Tarasov V., Jung P., Verdoodt B., Lodygin D., Epanchintsev A., Menssen A., Meister G., Hermeking H. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007, 6:1586-1593.
207. Tellez C.S., Juri D.E., Do K., Bernauer A.M., Thomas C.L., Damiani L.A., Tessema M., Leng S., Belinsky S.A. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011, 71(8):3087-3097.
208. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell. Biol. 2006, 7:131-142.
209. Tili E., Michaille J.J., Liu C.G., Alder H., Taccioli C., Volinia S., Calin G.A., Croce C.M. GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Res. 2010, 38:7673-7688.
210. To K.K., Polgar O., Huff L.M., Morisaki K., Bates S.E. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol. Cancer Res. 2008, 6:151-164.
211. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
212. Torres-Padilla M.E., Parfitt D.E., Kouzarides T., Zernicka-Goetz M. Histone arginine methylation regulates pluripotency in the early mouse embryo. Nature 2007, 445:214-218.
213. Trowbridge J.J., Sinha A.U., Zhu N., Li M., Armstrong S.A., Orkin S.H. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 2012, 26:344-349.
214. Tsai H.C., Baylin S.B. Cancer epigenetics: linking basic biology to clinical medicine. Cell. Res. 2011, 21:502-517.
215. Tsang D.P., Cheng A.S. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J. Gastroenterol. Hepatol. 2011, 26:19-27.
216. Uziel T., Karginov F.V., Xie S., Parker J.S., Wang Y.D., Gajjar A., He L., Ellison D., Gilbertson R.J., Hannon G., Roussel M.F. The miR-17∼92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2812-2817.
217. Vallejo D.M., Caparros E., Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. Embo J. 2011, 30:756-769.
218. Vermeulen L., De Sousa E.M.F., van der Heijden M., Cameron K., de Jong J.H., Borovski T., Tuynman J.B., Todaro M., Merz C., Rodermond H., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell. Biol. 2010, 12:468-476.
219. Vincan E., Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin. Exp. Metastasis 2008, 25:657-663.
220. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
221. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
222. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.
223. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
224. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2257-2261.
225. Wang B., Hsu S.H., Majumder S., Kutay H., Huang W., Jacob S.T., Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010, 29:1787-1797.
226. Wang J., Lu F., Ren Q., Sun H., Xu Z., Lan R., Liu Y., Ward D., Quan J., Ye T., Zhang H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011, 71:7238-7249.
227. Wang X., Lam E.K., Zhang J., Jin H., Sung J.J. MicroRNA-122a functions as a novel tumor suppressor downstream of adenomatous polyposis coli in gastrointestinal cancers. Biochem. Biophys. Res. Commun. 2009, 387:376-380.
228. Wang, Y., Shang, Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res., (pii: S0014-4827(12)00361-8). http://dx.doi.org/10.1016/j.yexcr.2012.07.019.
229. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
230. Wellner U., Schubert J., Burk U.C., Schmalhofer O., Zhu F., Sonntag A., Waldvogel B., Vannier C., Darling D., zur Hausen A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell. Biol. 2009, 11:1487-1495.
231. Weng A.P., Millholland J.M., Yashiro-Ohtani Y., Arcangeli M.L., Lau A., Wai C., Del Bianco C., Rodriguez C.G., Sai H., Tobias J., et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006, 20:2096-2109.
232. White A.C., Tran K., Khuu J., Dang C., Cui Y., Binder S.W., Lowry W.E. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(18):7425-7430.
233. Widschwendter M., Fiegl H., Egle D., Mueller-Holzner E., Spizzo G., Marth C., Weisenberger D.J., Campan M., Young J., Jacobs I., Laird P.W. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39:157-158.
234. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344.
235. Xu Y., Sun J., Xu J., Li Q., Guo Y., Zhang Q. miR-21 is a promising novel biomarker for lymph node metastasis in patients with gastric cancer. Gastroenterol. Res. Pract 2012, 2012, 640168.
236. Yang J., Chai L., Liu F., Fink L.M., Lin P., Silberstein L.E., Amin H.M., Ward D.C., Ma Y. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:10494-10499.
237. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
238. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell. 2008, 14:818-829.
239. Yang, S., Li, Y., Gao, J., Zhang, T., Li, S., Luo, A., Chen, H., Ding, F., Wang, X., Liu, Z. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene, http://dx.doi.org/10.1038/onc.2012.432.
240. Yang X., Lin X., Zhong X., Kaur S., Li N., Liang S., Lassus H., Wang L., Katsaros D., Montone K., et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res. 2010, 70:9463-9472.
241. Yang X.J. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res. 2004, 32:959-976.
242. Yi J.M., Tsai H.C., Glockner S.C., Lin S., Ohm J.E., Easwaran H., James C.D., Costello J.F., Riggins G., Eberhart C.G., et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008, 68:8094-8103.
243. Yu F., Jiao Y., Zhu Y., Wang Y., Zhu J., Cui X., Liu Y., He Y., Park E.Y., Zhang H., et al. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells. J. Biol. Chem. 2012, 287:465-473.
244. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., Huang Y., Hu X., Su F., Lieberman J., Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
245. Zhang H., Li W., Nan F., Ren F., Wang H., Xu Y., Zhang F. MicroRNA expression profile of colon cancer stem-like cells in HT29 adenocarcinoma cell line. Biochem. Biophys. Res. Commun. 2011, 404:273-278.
246. Zhang W., Glockner S.C., Guo M., Machida E.O., Wang D.H., Easwaran H., Van Neste L., Herman J.G., Schuebel K.E., Watkins D.N., et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008, 68:2764-2772.
247. Zhao Z., Tavoosidana G., Sjolinder M., Gondor A., Mariano P., Wang S., Kanduri C., Lezcano M., Sandhu K.S., Singh U., et al. Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nat. Genet. 2006, 38:1341-1347.
248. Zhou A.D., Diao L.T., Xu H., Xiao Z.D., Li J.H., Zhou H., Qu L.H. beta-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/beta-catenin-signaling pathway. Oncogene 2012, 31:2968-2978.